Pulmonx (LUNG) Projected to Post Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $23.46 million for the quarter.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.01. The company had revenue of $22.54 million during the quarter, compared to the consensus estimate of $22.03 million. Pulmonx had a negative net margin of 65.27% and a negative return on equity of 63.69%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Trading Up 0.6%

NASDAQ:LUNG opened at $3.34 on Monday. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.97 and a quick ratio of 4.29. The firm has a 50-day moving average of $2.98 and a 200-day moving average of $5.09. The company has a market cap of $134.47 million, a PE ratio of -2.32 and a beta of 0.45. Pulmonx has a one year low of $2.50 and a one year high of $9.37.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LUNG shares. Canaccord Genuity Group decreased their price target on Pulmonx from $16.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, May 1st. Citigroup cut their price target on shares of Pulmonx from $6.50 to $4.15 and set a “neutral” rating on the stock in a report on Thursday, May 22nd. D. Boral Capital restated a “buy” rating and set a $17.00 price target on shares of Pulmonx in a report on Thursday, May 1st. Finally, Piper Sandler restated an “overweight” rating and set a $9.00 price target (down from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.53.

Insider Activity at Pulmonx

In related news, CFO Mehul Joshi sold 8,061 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total transaction of $25,230.93. Following the sale, the chief financial officer directly owned 213,925 shares in the company, valued at approximately $669,585.25. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Daniel P. Florin purchased 23,321 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The shares were acquired at an average price of $3.06 per share, for a total transaction of $71,362.26. Following the completion of the purchase, the director directly owned 117,231 shares in the company, valued at $358,726.86. This represents a 24.83% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 43,388 shares of company stock worth $136,044 in the last ninety days. Insiders own 6.80% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.